United Therapeutics Corporation $UTHR Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,844 shares of the biotechnology company’s stock after selling 3,460 shares during the period. California State Teachers Retirement System’s holdings in United Therapeutics were worth $35,486,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of UTHR. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research report on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $648.33.

United Therapeutics Trading Down 1.5%

UTHR stock opened at $517.71 on Friday. The firm has a 50-day moving average of $543.63 and a two-hundred day moving average of $532.44. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a market cap of $21.98 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 1.76 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the sale, the director directly owned 450 shares of the company’s stock, valued at $247,765.50. This trade represents a 41.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,960,240.32. The trade was a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 502,833 shares of company stock worth $279,377,162 in the last three months. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.